Ash Alizadeh, MD/PhD 🇺🇸
@AshAlizadeh
Followers
4K
Following
4K
Media
105
Statuses
1K
@Stanford Professor. Hematologist/Oncologist & Cancer Geneticist. Computers, tumor genomes, ctDNA, immunology, lymphoma, diagnostics.
Stanford, CA
Joined June 2009
Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵.
nejm.org
The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. We reviewed our ...
12
71
217
Whoa. Not just DFS but significant OS improvements make this an especially remarkable result! A major step forward for patients with bladder cancer and for ctDNA driven trials across cancers.
In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO.
0
0
8
An honor and a privilege to have been part of this collaborative study across frontline DLBCL trials.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L. Read the full article. #lymsm.
1
2
33
RT @RoschewskiMD: Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology .
ascopubs.org
PurposeLarge B-cell lymphomas (LBCL) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as...
0
20
0
RT @LMikkMD: Extending access for life-saving CAR-T therapies!
fda.gov
The REMS for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated because the FDA has determined that a REMS is no longer...
0
6
0
RT @ManelEsteller: I couldn’t resist highlighting the beautiful first page of our recent @BCD_AACR @AACR article, which unveils the two dis….
0
5
0
RT @drjgauthier: Excited to share this new publication in @Haematologica from our group @fredhutch investigating the impact of extramedulla….
0
3
0
RT @LiaPalomba: Grazie Franco and the whole Lugano/Bellinzona team for yet another great #ICML. See you in 2027!
0
1
0
RT @MarcJacksonLA: $LYEL .- Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses….
stocktitan.net
New dual-targeting CAR T-cell therapy demonstrates exceptional durability in aggressive lymphoma treatment. 71% maintained complete response at 6+ months. See full results.
0
3
0
RT @Dr_Daniel_Molin: The big debate 3: Smith vs Nowakowski: Is Pola-R-CHP the new standard for all DLBCL? No.
0
6
0
RT @vit_prochazka: @Dr_Daniel_Molin Congrats @GregNowakowski ! It was a clear win at 80:20, wonderful presentation! You nailed it!.
0
1
0
RT @DrAEvens: 🚨🚨We are pleased to publish the next output via the HoLISTIC consortium (Hodgkin Lymphoma.International STudy for Individual….
0
24
0
RT @Eddie_Cliff: Data from the Shipp lab @DanaFarber support that the benefit of polatuzumab in 1L DLBCL is isolated to a subgroup of patie….
0
12
0
RT @Shayan86: There's been a sharp fall in the number of videos recorded by Iranians and posted to social media documenting Israeli strikes….
0
185
0
RT @majorajay: ICYMI: tafa-R^2 approved by FDA for R/R FL with at least one prior line of systemic therapy. #18ICML #lymsm .
fda.gov
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.
0
7
0
RT @Eddie_Cliff: @Giguere_P @BCCancer @AshAlizadeh @AdamR_PhD @dgermain21 @icmlugano Here’s an updated version of our table - in addition t….
0
7
0
RT @DrLizBrem: Is pola-Gem Ox any better than pola alone? It causes more neuropathy. Let’s hope the future sees us moving beyond R-GemOx as….
0
4
0
RT @adamfeuerstein: BREAKING: Top gene therapy regulator forced out at FDA.Nicole Verdun and her deputy placed on leave. .
statnews.com
Nicole Verdun, top gene therapy regulator at the FDA, has been forced out of the agency.
0
30
0
RT @UCSFHospitals: We are deeply saddened by the passing of Dr. Atul Butte, a visionary scientist, educator and leader whose work reshaped….
0
27
0
RT @zakkohane: Celebration of the life of Atul Butte. Join colleagues from three universities to celebrate him at 10 am PST on Saturday. h….
0
76
0